Loading
Latest filing published 08 Dec 2023 for SAB Biotherapeutics, Inc., €1,422.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Eddie Joe Sullivan on record concern SAB Biotherapeutics, Inc., in the capacity of chief executive. Over a trading history stretching from 7 October 2021 to 7 December 2023, the count stands at 4 filings.
Every open-market trade on record is a purchase: 2 purchases worth €12k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants. In 2023 alone, the filings show 1 purchase and no sales.
The newest entry dates from 8 December 2023: an open-market purchase of €1,422, in SAB Biotherapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations